Introduction {#Sec1}
============

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with an increased risk of subclinical \[[@CR1],[@CR2]\], clinical cardiovascular disease (CVD) \[[@CR3]\] and early cardiovascular (CV) mortality \[[@CR4]\]. Chronic inflammation plays a pivotal role in the pathogenesis of subclinical CVD in PsA patients \[[@CR5],[@CR6]\]. Inflammation is involved in foam cell formation, endothelial dysfunction and Th1 cytokine production, which leads to the development of arterial dysfunction \[[@CR7]\] and atherosclerotic plaque \[[@CR8]\]. However, inflammatory markers including erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) failed to differentiate PsA patients with or without subclinical atherosclerosis in cross-sectional studies \[[@CR1],[@CR9]\], most likely because PsA is a chronic relapsing condition in which inflammation may fluctuate over time. The chronic inflammatory burden may be better represented by the cumulative average of inflammatory markers than the measurement of these markers at a single time point. Eder and colleagues have recently reported that increased inflammatory burden over time, as reflected by cumulative average of ESR, is associated with the extent of atherosclerotic plaques in PsA patients from a prospective cohort \[[@CR10]\]. This association is attenuated after adjustment for traditional CV risk factors. In patients with rheumatoid arthritis (RA), a prospectively study also demonstrated that higher average CRP levels are associated with incident or progressive plaque, but only in patients with high CVD risk \[[@CR11]\]. In RA, the average CRP correlates with the presence of subclinical atherosclerosis measured by carotid intima-media thickness (IMT) \[[@CR12]\]. Also, the average CRP is associated with an increased risk of CV events and mortality in patients with long-standing RA \[[@CR13]\]. Whether chronic inflammation can accelerate atherogenesis independently or mediate it via adverse modification of CV risk factors remains uncertain.

Arterial stiffness is an independent predictor of CV events and mortality \[[@CR14]\]. Pulse wave velocity (PWV) is a measure of early structural vascular changes, which is determined by the elasticity and other properties of the artery, and is correlated with arterial distensibility and stiffness. An increase in brachial-ankle PWV by 100 cm/s corresponds to an age-, sex-, and risk factor-adjusted increase of 12% in total CV events, and 13% in CV mortality, respectively \[[@CR15]\]. By applying a cutoff value of 1450 cm/s, brachial-ankle PWV was found to discriminate normal subjects from those with CVD or atherosclerotic risk factors with sensitivity of 62.1% and specificity of 69.5% in a large-scale population-based study involving 21,094 Chinese subjects \[[@CR16]\]. Two previous case--control studies failed to find a correlation between ESR or CRP and PWV in PsA patients \[[@CR17],[@CR18]\]. However, these studies were limited by small sample size and cross-sectional study design and were unable to assess the effect of cumulative inflammation over time. The effect of cumulative inflammatory burden in arterial stiffness in patients with RA is controversial \[[@CR19],[@CR20]\]. Whether cumulative inflammatory burden over time may affect arterial stiffness as assessed by PWV in PsA has never been explored. We hypothesize that PsA patients with higher cumulative inflammatory burden (as measured by cumulative averages of the area under the curve (AUC) for ESR and CRP) would have increased arterial stiffness. In this study, we first compared the arterial stiffness between PsA patients and healthy controls. Second, we examined whether the cumulative inflammatory burden over time is associated with an increase in arterial stiffness in a prospective cohort of PsA patients.

Methods {#Sec2}
=======

Patients and healthy controls {#Sec3}
-----------------------------

Eighty-two PsA patients who participated in a prior subclinical study of atherosclerosis in PsA \[[@CR1]\] were recruited for a PWV assessment between 2012 and 2013. Briefly, all participants fulfilled the Classification of Psoriatic Arthritis (CASPAR) criteria \[[@CR21]\] and had been prospectively followed at the rheumatology clinic of two regional hospitals (The Prince of Wales Hospital and the Alice Ho Miu Ling Nethersole Hospital) since 2006 to 2007 (baseline visit). Exclusion criteria at baseline included overt CVD (including myocardial infarction, angina, stroke, and transient ischemic attack), inability to provide informed consent, clinically significant renal disease (serum creatinine level \>270 mol/L), or pregnancy. Patients were assessed by rheumatologists every 4 to 6 months, which included a complete history, physical examination and laboratory evaluation: 72 patients who completed the last follow-up visit and had a successful brachial-ankle PWV assessment were included in the analysis.

We recruited 47 healthy controls from a broad spectrum of hospital staff. None of the controls had a known history of hypertension, diabetes, hyperlipidemia, or overt CVD (including myocardial infarction, angina, stroke, or transient ischemic attack), or family history of CVD.

Ethics approval was obtained from the Ethics Committee of The Chinese University of Hong Kong-New Territories East Cluster Hospitals, and written informed consent was obtained from all participants according to the Declaration of Helsinki.

Clinical interview at baseline and last follow-up visit {#Sec4}
-------------------------------------------------------

Pain and physicians' and patients' global assessments were evaluated using a 100-point visual analog scale, where 0 indicated excellent well-being and 100 indicated feeling extremely unwell. Physical examination included recording the number of tender and swollen joints using the 68 tender-joint/66 swollen-joint count, the presence of dactylitis, and the number of permanently deformed joints. The Health Assessment Questionnaire (HAQ) was used to evaluate physical function \[[@CR22]\], and the Psoriasis Area and Severity Index (PASI) was used to assess the extent of skin involvement \[[@CR23]\]. Overall disease activity was assessed using the Disease Activity in Psoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) scores \[[@CR24]\]. Anthropomorphic measurements including height, weight, and waist and hip circumference, and two consecutive blood pressure (BP) readings in the sitting position and heart rate were recorded. Other data obtained from PsA patients through the interview and chart review included smoking and drinking habits, history of diabetes, hypertension, hypercholesterolemia and overt CVD. Drug history was retrieved from case notes or elicited during the clinical assessment. All patients were interviewed and examined using standardized data collection instruments.

Laboratory tests {#Sec5}
----------------

Complete blood count, liver and renal function tests, ESR and CRP were checked at every visit. Fasting blood glucose, and lipid profile (total cholesterol (TC), low-density lipoprotein-cholesterol (LDL), high-density lipoprotein-cholesterol (HDL), and triglycerides) were checked at baseline and the last visit. Cumulative inflammation over time was represented by the cumulative averages of ESR (ca-ESR) and CRP (ca-CRP).

Pulse wave velocity {#Sec6}
-------------------

Brachial-ankle PWV was assessed noninvasively in subjects in the supine position by a dedicated tonometry system (Non-Invasive Vascular Profile Device VP-2000; Omron Healthcare, Inc, Bannockburn, IL, USA) as described previously \[[@CR25]\]. All PWV measurements were performed twice at each side of the body by a single skilled operator. The means of overall PWV measurements were recorded. The intra-class correlation coefficient (ICC) for intraobserver reliability was 0.84 \[[@CR26]\].

Statistical analysis {#Sec7}
--------------------

Results are expressed as mean ± SD or median (interquartile range) as appropriate. Comparisons between two groups were assessed using the Student's *t*-test or Mann--Whitney *U*-test for continuous variables and the chi-square (χ^2^) test for categorical variables. Analysis of covariance (ANCOVA) was used to compare means of PWV between PsA and control subjects by adjusting for parameters that were distributed differently between groups. Spearman's correlation was used to evaluate bivariate correlation. ca-ESR and ca-CRP were calculated from the AUC of all available measurements divided by the total number of months of follow-up. Univariate analysis was performed to ascertain the association between clinical parameters and PWV. The cutoff value for CV and atherosclerotic risk, which was derived from the large-scale Chinese population-based study \[[@CR16]\], was used to divide the PsA patients into a high-PWV group (≥1,450 cm/s) or low-PWV group (\<1,450 cm/s). Multivariable logistic regression analysis was used to determine the independent predictor(s) for being in the high-PWV group. All variables with *P* \<0.1 in the univariate analysis were included in the multivariate analysis. All statistical analyses were conducted using IBM SPSS Statistics Version 22 (IBM, Armonk, NY, USA). A minimal level of significance of *P* \<0.05 is used.

Results {#Sec8}
=======

Clinical features of PsA patients {#Sec9}
---------------------------------

A total of 72 (36 male and 36 female) PsA patients were included in the analysis. At baseline, the mean ± SD age was 49.6 ± 11.7 years and the median (IQR) disease duration was 9.2 (2.4 to 14.1) years. The median follow-up duration from baseline to the time of PWV assessment (last visit) was 6.5 (range: 4.8 to 7.7) years. Table [1](#Tab1){ref-type="table"} summarized the clinical features of the patients at baseline and last visit. Compared with baseline, significant improvement in disease activity parameters (number of tender and swollen joint counts, pain, DAPSA and CRP) and physical function (HAQ) were observed at the last visit, although the damaged joint count increased. CV risk factors remained stable except for systolic blood pressure (SBP) and HDL levels decreased. More patients were taking anti-hypertensive drugs, statins and biologic disease modifying anti-rheumatic drugs (DMARDs) at the last visit.Table 1**Clinical features at baseline and last visit in all PsA patientsBaselineLast visit*P*** **-valueMale gender, n (%)**36 (50.0%)**Age, years**49.6 ± 11.755.9 ± 11.6**Psoriatic arthritis (PsA) characteristics**  PsA disease duration, years9.2 (2.4 to 14.10)15.7 (8.5 to 21.2)  Tender joint count, 0 to 682 (0 to 8)1 (0 to 4)0.033  Swollen joint count, 0 to 660 (0 to 3)0 (0 to 1)0.032  Damaged joint count, 0 to 682 (0 to 5)2 (0 to 6)0.031  Visual analog scale pain, 0 to 10050 (30 to 66)30 (20 to 58)0.001  Patients' global assessment, 0 to 10050 (30 to 60)40 (20 to 60)0.298  Physicians' global assessment, 0 to 10020 (0 to 30)20 (5 to 35)0.683  Psoriasis Area and Severity Index, 0 to 722.6 (0.9 to 7.5)1.8 (0.4 to 6.3)0.309  Health assessment questionnaire, 0 to 30.38 (0.12 to 0.94)0.25 (0 to 0.69)0.043  Minimal disease activity, n (%)16 (22.2%)14 (19.4%)0.539  Disease Activity in Psoriatic Arthritis, 0 to 16416 (8 to 21)11 (6 to 16)0.010  Erythrocyte sedimentation rate, mm/1st h23 (10 to 37)18 (8 to 34)0.357  C-reactive protein, mg/dl0.4 (0.2 to 1.3)0.3 (0.1 to 0.7)0.016**Cardiovascular risk factors**  Body weight, kg65.2 ± 12.065.7 ± 11.60.436  Body height, cm161 ± 8  Systolic blood pressure, mmHg136 ± 22127 ± 15\<0.001  Hypertension, n (%)36 (50.0%)44 (61.1%)0.555  Diabetes, n (%)16 (44.4%)16 (44.4%)1.000  Framingham 10-year CVD risk \>10%, n (%)30 (41.7%)36 (50.0%)0.316  Total cholesterol, mmol/L5.1 ± 0.94.9 ± 0.80.073  High-density lipoprotein cholesterol, mmol/L1.6 ± 0.51.4 ± 0.4\<0.001  Triglycerides, mmol/L1.5 ± 0.91.5 ± 0.90.558  Fasting glucose, mmol/L5.5 ± 1.35.5 ± 1.60.861**Medications, n (%)**  Anti-hypertensive drugs20 (27.8%)42 (58.3%)\<0.001  Statins1 (1.4%)14 (19.4%)\<0.001  Nonsteroidal anti-inflammatory drugs33 (45.8%)31 (43.1%)0.737  Steroids4 (5.6%)3 (4.2%)0.999  Disease-modifying antirheumatic drugs36 (50.0%)40 (55.6%)0.504  Biologics0 (0%)11 (15.4%)0.001Values are presented as number (percentage), median (interquatile range) or mean ± SD. CVD, cardiovascular disease.

PWV in PsA patients and control subjects {#Sec10}
----------------------------------------

The mean PWV in PsA patients and control subjects were 1,533 ± 307 cm/s and 1,219 ± 157 cm/s, respectively (*P* \<0.001) (Figure [1](#Fig1){ref-type="fig"}A). The control subjects were significantly younger (43.1 ± 10.2 years versus 55.9 ± 11.6 years, *P* \<0.001), had higher proportion of women (72.3% versus 50.0%, *P* = 0.015) and a lower body weight (58.2 ± 8.7 kg versus 65.7 ± 11.6 kg, *P* \<0.001) at PWV assessment compared with the PsA patients. However, after adjustment for age, gender and body weight, the adjusted mean PWV was still significantly greater in PsA patients compared with control subjects (1,466 ± 29 cm/s versus 1,323 ± 38 cm/s, *P* = 0.008) (Figure [1](#Fig1){ref-type="fig"}B). If patients with hypertension, diabetes or hyperlipidemia were excluded, the age, gender, and body weight-adjusted mean for PsA patients (n = 20) and control subjects were 1,394 ± 46 and 1,248 ± 29 cm/s, respectively (*P* = 0.013) (Figure [1](#Fig1){ref-type="fig"}C).Figure 1**Pulse wave velocity (PWV) in control subjects and patients with psoriatic arthritis (PsA). (A)** Unadjusted mean in control subjects (n = 47) and all PsA patients (n = 72). **(B)** Mean adjusted by age, gender and body weight in control subjects and all PsA patients. **(C)** Mean adjusted by age, gender and body weight in control subjects and PsA patients without hypertension, diabetes or hyperlipidemia (n = 20).

Association between traditional cardiovascular risk factors and PWV {#Sec11}
-------------------------------------------------------------------

The associations between PWV and clinical features at both baseline and the last visit (PWV assessment visit) are shown in Table [2](#Tab2){ref-type="table"}. At PWV assessment, patients in the high-PWV group (n = 38) were significantly older, had higher SBP and Framingham 10-year CVD risk score, were more likely to have diabetes and hypertension, and to be treated with anti-hypertensive drugs compared with the low-PWV group (n = 34) (all *P* \<0.05).Table 2**Clinical features at baseline and last follow-up visit in patients in the high and low pulse-wave velocity (PWV) groupsBaselineLast visitLow PWVHigh PWV*P*** **-valueLow PWVHigh PWV*P*** **-valueMale gender, n (%)**17 (50.0%)19 (50.0%)1.00017 (50.0%)19 (50.0%)1.000**Age, years43.3 ± 10.255.2 ± 10.0\<0.00149.6 ± 10.161.6 ± 9.9\<0.001Psoriatic arthritis (PsA) characteristics**  PsA disease duration, years**7.6 ± 7.010.7 ± 7.50.07313.9 ± 7.217.1 ± 7.80.075**  Tender joint count, 0 to 682 (0 to 6)3 (0 to 8)0.5511 (0 to 3)1 (0 to 5)0.248  Swollen joint count, 0 to 660 (0 to 2)1 (0 to 3)0.8270 (0 to 1)0 (0 to 1)0.376  Damaged joint count, 0 to 681 (0 to 3)2 (0 to 6)0.118**0 (0 to 4)4 (0 to 8)0.010**  Visual analog scale pain, 0 to 10040 (20 to 60)50 (30 to 70)0.21230 (20 to 50)30 (20 to 60)0.964  Patients' global assessment, 0 to 10050 (20 to 60)50 (40 to 60)0.25850 (20 to 60)33 (20 to 60)0.654  Physicians' global assessment, 0 to 10010 (0 to 20)20 (5 to 30)0.46219 (6 to 35)20 (7 to 30)0.399  Psoriasis Area and Severity Index, 0 to 722.6 (1.0 to 7.3)3.0 (0.7 to 7.7)0.8791.8 (0.6 to 5.4)1.7 (0.3 to 7.4)0.879  Health assessment questionnaire, 0 to 30.25 (0.13 to 0.63)0.56 (0.13 to 1.00)0.1200.13 (0 to 0.50)0.38 (0 to 1.13)0.146  Minimal disease activity, n (%)10 (29.4%)6 (15.8%)0.1656 (17.6%)8 (21.1%)0.715  Disease Activity in Psoriatic Arthritis, 0 to 16414 (7 to 19)17 (12 to 22)0.13211 (7 to 15)12 (5 to 18)0.827  Erythrocyte sedimentation rate, mm/1st h**16 (7 to 34)27 (13 to 56)0.04811 (5 to 22)29 (13 to 56)\<0.001**  C-reactive protein, mg/dl0.3 (0.1 to 1.2)0.5 (0.2 to 1.3)0.527**0.2 (0.1 to 0.5)0.4 (0.2 to 0.8)0.023Cardiovascular risk factors**  Body weight, kg66.1 ± 12.464.4 ± 11.80.540**68.1 ± 12.063.6 ± 11.00.099**  Body height, cm161 ± 8161 ± 90.891  Systolic blood pressure, mmHg132 ± 23140 ± 210.113**121 ± 13132 ± 160.002**  Hypertension, n (%)**10 (29.4%)26 (68.4%)0.00115 (44.1%)29 (76.3%)0.005**  Diabetes, n (%)**3 (8.8%)13 (34.2%)0.0103 (8.8%)13 (34.2%)0.010**  Framingham 10-year CVD risk \>10%, n (%)**8 (23.5%)22 (57.9%)0.0039 (26.5%)27 (71.1%)\<0.001**  Total cholesterol, mmol/L5.1 ± 0.95.1 ± 1.00.8145.0 ± 1.04.8 ± 0.70.468  High-density lipoprotein cholesterol, mmol/L1.6 ± 0.51.6 ± 0.50.7821.5 ± 0.41.4 ± 0.40.467  Triglycerides, mmol/L1.4 ± 0.71.6 ± 1.10.2851.3 ± 0.81.5 ± 1.00.363  Fasting glucose, mmol/L5.3 ± 1.65.7 ± 1.00.2275.2 ± 1.05.6 ± 1.90.287**Medications, n (%)**  Anti-hypertensive drugs**3 (8.8%)17 (44.7%)\<0.00114 (41.2%)28 (73.7%)0.005**  Statins0 (0%)1 (2.6%)1.0007 (20.6%)7 (18.4%)0.817  Nonsteroidal anti-inflammatory drugs13 (38.2%)20 (52.6%)0.22116 (47.1%)15 (39.5%)0.516  Steroids2 (5.9%)2 (5.3%)0.9991 (2.9%)2 (5.3%)0.999  Disease-modifying antirheumatic drugs15 (44.1%)21 (55.3%)0.34518 (52.9%)22 (57.9%)0.673  Biologics0 (0%)0 (0%)N.S.7 (20.6%)4 (10.5%)0.236Variables with *P*-values \<0.1 (values in bold text) were candidates for multivariate analysis. Values are presented as number (percentage), median (interquatile range), or mean ± SD.

Association between disease-related parameters and PWV {#Sec12}
------------------------------------------------------

Disease-related variables were compared between the two PWV groups (Table [2](#Tab2){ref-type="table"}). The high-PWV group had a trend of longer disease duration (*P* \<0.1). At baseline, the high-PWV group had significantly higher ESR levels compared with patients in the low-PWV group (*P* = 0.048). At PWV assessment, the high-PWV group had significantly higher damaged joint count, ESR and CRP levels.

Association between cumulative inflammatory burden and PWV {#Sec13}
----------------------------------------------------------

The median ca-ESR was 24 (12 to 38) mm/1st h and the median ca-CRP was 0.6 (0.2 to 1.1) mg/dl in the PsA patients. There was a significant correlation between PWV and ca-ESR (Spearman's rho 0.390, *P* = 0.001) but not ca-CRP (0.222, *P* = 0.061). The high-PWV group had significantly higher ca-ESR (31 (21 to 44) versus 17 (10 to 30) mm/1st h, *P* \<0.001) and ca-CRP (0.7 (0.3 to 1.4) versus 0.4 (0.2 to 0.7) mg/dl, *P* = 0.029) compared with the low-PWV group (Figure [2](#Fig2){ref-type="fig"}).Figure 2**Cumulative inflammatory burden and pulse wave velocity (PWV).** Cumulative average of erythrocyte sedimentation rate (ca-ESR) and C-reactive protein (CRP) in the low PWV group (PWV \<1,450 cm/s, n = 34) and the high-PWV group (PWV ≥1,450 cm/s, n = 38).

The association between the cumulative inflammatory burden and PWV was assessed by regression analysis (Table [3](#Tab3){ref-type="table"}). High ca-ESR (defined as ≥75th percentile: 37 mm/1st h) was associated with a higher likelihood of being in the high-PWV group after adjustment for other clinical and CV risk factors at baseline (OR 9.455 (95% CI 1.939, 46.093), *P* = 0.005) or last visit (OR 9.111 (95% CI 1.875, 44.275), *P* = 0.006) (Table [3](#Tab3){ref-type="table"}). In contrast, high ca-CRP (defined as ≥75th percentile 1.2 mg/dl) was not associated with a higher likelihood of being in the high-PWV group (Table [3](#Tab3){ref-type="table"}).Table 3**Association between cumulative inflammatory burden and high-PWV group by multivariable logistic regressionModel** ^**a**^**FactorsOdds ratio95% CI*P*** **-value**Baseline^b^High cumulative ESR^d^9.4551.939, 46.0930.005High cumulative CRP^e^1.7360.294, 10.2680.543Last visit^c^High cumulative ESR^d^9.1111.875, 44.2750.006High cumulative CRP^e^0.8880.088, 9.0070.920^a^Adjusted for parameters at baseline or last follow up. ^b^Parameters entered: age, psoriatic arthritis (PsA) duration, hypertension, diabetes, Framingham risk score, use of anti-hypertension drugs, high erythrocyte sedimentation rate (ESR)^d^, cumulative average (ca)-ESR^d^ and ca-C-reactive protein (CRP)^e^. ^c^Parameters entered: age, PsA duration, body weight, systolic blood pressure, hypertension, diabetes, damaged joints count, use of anti-hypertension drugs, Framingham risk score, high ESR^d^ and CRP^e^, high ca-ESR^d^ and ca-CRP^e^. ^d^Defined as ≥75th percentile: 37 mm/1st h. ^e^Defined as ≥75th percentile: 1.2 mg/dl.

Older age was the other independent risk factor associated with a higher likelihood of being in the high-PWV group (adjusted for baseline parameters: OR 1.137 (95% CI 1.058, 1.223), *P* \<0.001; adjusted for last-visit parameters: OR 1.135 (95% CI 1.056, 1.219), *P* = 0.001).

Discussion {#Sec14}
==========

This is the first study to assess the association between cumulative inflammatory burden and arterial stiffness in PsA patients. High cumulative inflammatory burden as reflected by the ca-ESR was a predictor for higher PWV independently of traditional CV risk factors and other disease activity parameters. We also confirmed that PWV is increased in PsA patients compared with healthy control subjects in a larger cohort.

We have demonstrated a significant correlation between ca-ESR and PWV (*P* = 0.001) and a marginally significant correlation between ca-CRP and PWV (*P* = 0.061), suggesting that chronic inflammation may have a causative role in the development of arterial dysfunction in PsA patients. These results were consistent with previous findings that cumulative inflammatory burden (ca-ESR) was associated with increased aortic augmentation index in RA \[[@CR19]\] and severity of carotid plaque in PsA \[[@CR10]\]. One previous study reported that PWV associated with current CRP levels, but not with historical measures of cumulative ESR inflammatory burden in RA \[[@CR20]\]. However, this study excluded patients with hypercholesterolemia and hypertension, and current smokers. In the current study ca-ESR, ca-CRP and single measurements of ESR and CRP at PWV assessment were associated with high PWV in the univariate analysis. Nonetheless, only ca-ESR was independently associated with high PWV in multivariate analysis after adjusting for other traditional CV risk factors and disease-related parameters, indicating that the cumulative inflammatory burden may better explain increased arterial stiffness than transient inflammatory status.

Different from ca-ESR, ca-CRP was not associated with PWV in multiple regression. A previous study from Eder *et al*. reported no association between ca-CRP and atherosclerosis in patients with PsA \[[@CR10]\] while Giles *et al*. \[[@CR11]\] reported that higher ca-CRP levels were associated with incident or progressive plaque, primarily in patients with elevated CVD risk in patients with RA. These seemingly contradictory findings may be explained by the relatively low levels of chronic inflammation that are commonly found in PsA compared with RA. A high-sensitivity (hs) CRP assay may be more informative, but was not available in our study. Serial monitoring of inflammatory markers including hsCRP should be considered in PsA patients.

Damaged joint count at the last visit was also associated with increased PWV in the univariate analysis. Indeed, damaged joint count could also represent the cumulative inflammatory burden and was found to be independently associated with atherosclerosis in RA \[[@CR27]\]. However, the significance of damaged joint count was lost after adjusting for ca-ESR and other CV risk factors in PsA patients.

We also confirmed that arterial stiffness is increased in PsA patients. PWV was significantly higher in PsA patients after adjustment for age, gender and body weight, and even after PsA patients with hypertension, diabetes or hyperlipidemia were excluded. This is consistent with other studies with smaller case numbers that measured arterial stiffness by aortic PWV \[[@CR17],[@CR18]\]. Costa *et al*. \[[@CR17]\] reported increased PWV in 20 PsA patients compared with 20 controls. Soy *et al*. \[[@CR18]\] also showed that PWV was higher in 9 PsA patients compared with 39 controls. In a previous study involving 73 PsA patients and 50 healthy controls, a significant increase in augmentation index was noticed, indicating impairment of both macrovascular and microvascular functions \[[@CR28]\].

Although increased overall mortality in PsA patients has been reported in some \[[@CR29]-[@CR32]\] but not all \[[@CR33],[@CR34]\] studies, previous data have consistently indicated an increased susceptibility to CVD and related mortality in PsA patients \[[@CR3],[@CR35]\]. Our results indicated that the increased CVD and related mortalities may be partly mediated by increased arterial stiffness through persistent chronic inflammation. Inflammation accelerates subclinical atherosclerosis probably through adverse modification of the traditional CV risk factors \[[@CR10]\]. In contrast, the association between cumulative inflammation and arterial stiffness was independent of traditional CV risk factors such as age, hypertension and diabetes. This may suggest that inflammation-induced arterial dysfunction is probably an early phase in the development of atherogenesis, and hence, PWV is a more sensitive marker reflecting changes in predominantly macrovascular functions in patients with rheumatic disease and chronic inflammation, compared to arterial remodeling as reflected by increased IMT and plaques.

PsA is associated with reduced levels of endothelial progenitor cells (EPCs) and impaired EPC function, leading to decreased release of nitric oxide (NO) \[[@CR36]\]. Inflammatory cells such as macrophages and polymorphonuclear neutrophils produce a variety of matrix metalloproteinases (MMPs), which can alter the balance of elastin/collagen \[[@CR37]\]. Chronic inflammation may also induce oxidative stress \[[@CR7]\]. All these changes will lead to arterial stiffening. Inflammation also interacts with other important pathways such as advanced glycation end products (AGEs), which can irreversibly bind to collagens, resulting in stiffer AGE-linked collagen \[[@CR38],[@CR39]\]. Moreover, AGEs can also promote inflammatory response through binding to the receptor (RAGE) and subsequently increase arterial stiffness \[[@CR40],[@CR41]\]. TNF-α is a key cytokine involved in the pathogenesis of PsA \[[@CR42]\], which can induce neutrophil chemotaxis, macrophage activation and superoxide production. This results in endothelial inflammation and dysfunction, and may contribute to the development of arterial damage \[[@CR43]\]. Data from a non-randomized case--control study in patients with inflammatory arthritis (RA, PsA and ankylosing spondylitis) showed that long-term use of anti-TNF-α therapy may result in a significant improvement in PWV compared to the non-treated group \[[@CR44]\]. Whether effective suppression of inflammation can improve arterial stiffness in PsA should be explored in future clinical trials.

The strength of our study was the inclusion of a large prospective cohort with long-term follow up. Patients with CV risk factors were not excluded so that our results can be generalized to the usual PsA patient population. Our study also has a few limitations. First, our results may not be applicable to PsA patients from other ethnic backgrounds. Second, the outcome of this study (PWV) is only a surrogate of clinical CV events. In patients with PsA or RA, there are virtually no data to suggest whether PWV is a good surrogate of future CVD events. Third, arterial stiffness was assessed by brachial-ankle PWV but not the gold standard, carotid-femoral PWV. However, brachial-ankle PWV is highly correlated with carotid-femoral PWV and may provide qualitatively similar information \[[@CR45]\]. Fourth, only baseline and last-visit clinical and traditional risk factors were adjusted for. With regards to the association between cumulative inflammatory burden and arterial stiffness, we have only addressed the role of cumulative averages of ESR and CRP. Unfortunately, we did not have data on other disease activity measures, for example, DAPSA and MDA during all the visits. It would be of interest for a future study to include a measure such as average mean DAPSA, or to determine whether achieving MDA for a prolonged period of time could be a potential predictor of arterial stiffness. Last but not least, baseline PWV measurement was not available to assess the relationship between cumulative inflammatory burden or the effect of treatment and the changes in arterial stiffness. Further prospective studies should be conducted to address this issue.

Conclusions {#Sec15}
===========

In conclusion, PsA patients have increased arterial stiffness compared with healthy control subjects. Cumulative inflammatory burden contributes to the increased arterial stiffness independent of traditional CV risk factors, suggesting that increasing arterial stiffness may be one of the mechanisms linking inflammation and CVD in PsA.
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